8 completed, 3 unknown, 1 active not recruiting, 1 recruiting. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 8, Unknown 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Overactive Bladder Syndrome: new trials by email Literature Review of Overactive Bladder Syndrome trials Research Report on Overactive Bladder Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms OnabotulinumtoxinA - Urinary Incontinence, Overactive Bladder Syndrome | Phase 2 / Phase 3 | Active not recruiting | Northwestern University | 66 | 2023-07-13 | 2026-11-06 |
| Oxybutynin for Post-surgical Bladder Pain and Urgency Oxybutynin Transdermal Patch, Oral Oxybutynin - Overactive Bladder Syndrome, Neuropathic Bladder | Phase 3 | Recruiting | University of California, Davis | 100 | 2021-09-01 | 2026-01-29 |
| Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin Mirabegron, Solifenacin - Overactive Bladder Syndrome | Phase 3 | Unknown | Far Eastern Memorial Hospital | 120 | 2019-08-01 | 2023-09-15 |
| Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin IncobotulinumtoxinA 100 UNT Injection [Xeomin], OnabotulinumtoxinA 100 UNT [Botox] - Overactive Bladder Syndrome | Phase 3 | Unknown | University Of Perugia | 140 | 2018-09-01 | 2020-11-06 |
| Herbal Patch for Overactive Bladder herbal patch, placebo patch - Overactive Bladder Syndrome | Phase 2 / Phase 3 | Completed | En Chu Kong Hospital | 66 | 2018-05-14 | 2019-10-25 |
| Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan mirabegron - Overactive Bladder Syndrome | Phase 3 | Unknown | Buddhist Tzu Chi General Hospital | 574 | 2015-11-16 | 2017-02-09 |
| Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan Mirabegron 25mg - Urinary Incontinence, Overactive Bladder Syndrome | Phase 3 | Completed | Buddhist Tzu Chi General Hospital | 168 | 2015-04-28 | 2017-02-23 |
| Fesoterodine "add-on" Male Overactive Bladder Study Fesoterodine, Placebo - Overactive Bladder Syndrome | Phase 3 | Completed | Pfizer | 947 | 2007-11-01 | 2011-02-18 |
| Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome SPM 907 - Overactive Bladder Syndrome | Phase 3 | Completed | Pfizer | 2004-07-01 | 2008-11-24 | |
| A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. Darifenacin, Placebo - Overactive Bladder Syndrome | Phase 3 | Completed | Novartis | 445 | 2004-04-01 | 2008-01-23 |
| Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome SPM 907 - Overactive Bladder Syndrome | Phase 3 | Completed | Pfizer | 2004-04-01 | 2008-11-24 | |
| A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome SPM 907 - Overactive Bladder Syndrome | Phase 3 | Completed | Pfizer | 2004-01-01 | 2008-05-05 | |
| A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder Darifenacin - Overactive Bladder Syndrome | Phase 3 | Completed | Novartis | 718 | 2002-04-01 | 2008-01-17 |
Urinary Bladder, Overactive (4) · Urinary Incontinence (3) · Urinary Bladder, Neurogenic (1) · Urinary Tract Infections (1) · Urologic Diseases (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Urogenital Diseases (6) · Lower Urinary Tract Symptoms (5) · Urinary Bladder Diseases (5) · Urologic Diseases (5) · Urological Manifestations (5) · Urination Disorders (3) · Infections (1) · Nervous System Diseases (1) · Neurologic Manifestations (1)
mirabegron (3) · Botulinum Toxins, Type A (2) · darifenacin (2) · Solifenacin Succinate (1) · Tolterodine Tartrate (1) · fesoterodine (1) · incobotulinumtoxinA (1) · oxybutynin (1)
Pfizer (4) · Buddhist Tzu Chi General Hospital (2) · Novartis (2) · En Chu Kong Hospital (1) · Far Eastern Memorial Hospital (1) · Northwestern University (1) · University Of Perugia (1) · University of California, Davis (1)
United States (6) · Germany (3) · Taiwan (3) · Belgium (1) · Brazil (1) · Canada (1) · Colombia (1) · Greece (1) · India (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Norway (1) · Philippines (1) · Poland (1)
Axel Steinert (2) · Amy Krambeck, MD (1) · Antonella Giannantoni, M.D. (1) · Brooke Derby (1) · Emanuele Rubilotta, MD (1) · Eric A Kurzrock, MD (1) · Hann-Chorng Kuo, M.D. (1) · Hann-Chorng Kuo, MD (1) · Matteo Balzarro, MD (1)
PMID 10925088, PMID 11176403, PMID 11857671, PMID 12894267, PMID 17385940, PMID 18663723, PMID 19625056, PMID 19683731, PMID 19941278, PMID 20121659, PMID 20171668, PMID 20723260, PMID 21130559, PMID 22182409, PMID 22385408, PMID 23819724, PMID 24052109, PMID 24140548, PMID 24477421, PMID 24560879, PMID 25623739, PMID 25851380, PMID 25897202, PMID 27779229, PMID 28443147, PMID 30266334, PMID 35881009, PMID 37160401